<DOC>
	<DOC>NCT00962091</DOC>
	<brief_summary>This is an open-label, multicenter, phase 1 study to evaluate the safety and pharmacokinetic properties of an oral solution and enteric-coated tablet (ECT) formulations of MLN8237 in patients with advanced solid tumors. This study will be conducted in 3 parts, A, B, and C.</brief_summary>
	<brief_title>Study of MLN8237 in Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Each patient must meet all of the following inclusion criteria to be enrolled in the study: 18 years or older Histologically or cytologically confirmed metastatic and/or advanced solid tumor Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Female patients who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or abstain from heterosexual Male patients who agree to practice effective barrier contraception or agree to abstain from heterosexual intercourse Voluntary written consent Suitable venous access for studyrequired blood sampling Measurable disease Recovered from effects of prior antineoplastic therapy Patients meeting any of the following exclusion criteria are not to be enrolled in the study: Female patients who are pregnant or lactating Serious medical or psychiatric illness that could interfere with protocol completion Major surgery within 14 days of first dose of MLN8237 Antineoplastic therapy, radiation therapy or any experimental therapy 21 days prior to first dose of MLN8237 Nitrosoureas or mitomycinC within 6 weeks before the first dose of MLN8237. Autologous stem cell transplant within 3 months before the first dose of MLN8237, or prior allogeneic stem cell transplant at any time. Active infection requiring systemic therapy, or other serious infection Inability to swallow oral medication Gastrointestinal (GI) disease or GI procedure that could interfere with oral absorption or tolerance of MLN8237 Symptomatic brain metastasis Uncontrolled cardiovascular condition Diagnosis or treatment of another malignancy within 2 years preceding first dose of study drug except nonmelanoma skin cancer or in situ malignancy completely resected Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C Lactoseintolerant (Parts A and B only) Prior history of metabolic acidosis (Parts A and B only) Use of enzymeinducing antiepileptic drugs such as phenytoin, carbamazepine or phenobarbital, or rifampin, rifabutin, rifapentine or St. John's wort within 14 days prior to the first dose of MLN8237 A medical condition requiring use of pancreatic enzymes; or daily, chronic , or regular use of proton pump inhibitors (PPI); or histamine (H2) receptor antagonists. Patients who intermittently use these medications must meet the following: No use of PPI within 7 days of first dose of MLN8237 No use of H2 antagonist or pancreatic enzymes within 24 hours of first dose of MLN8237 Patients requiring full systemic anticoagulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Area under the plasma concentration versus time curve (AUC)</keyword>
	<keyword>Maximum plasma concentration (Cmax)</keyword>
	<keyword>Area under the plasma concentration versus time curve zero to the time of the last quantifiable concentration (AUC0-tlast)</keyword>
	<keyword>Confidence intervals (CI)</keyword>
	<keyword>Time of first observed maximum plasma concentration (Tmax)</keyword>
</DOC>